Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 20/20 | 0.58 |
| ▸ | JAK2 | O60674 | 11/20 | 0.58 |
| ▸ | JAK1 | P23458 | 11/20 | 0.58 |
| ▸ | TYK2 | P29597 | 6/20 | 0.58 |
| ▸ | PKN2 | Q16513 | 4/20 | 0.54 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.54 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.54 |
| ▸ | STK3 | Q13188 | 3/20 | 0.54 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.54 |
| ▸ | CAMK2D | Q13557 | 3/20 | 0.54 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.54 |
| ▸ | MARK3 | P27448 | 2/20 | 0.54 |
| ▸ | MARK2 | Q7KZI7 | 2/20 | 0.54 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.54 |
| ▸ | DCLK1 | O15075 | 2/20 | 0.54 |
| ▸ | ABL1 | P00519 | 2/20 | 0.54 |
| ▸ | LCK | P06239 | 2/20 | 0.54 |
| ▸ | FYN | P06241 | 2/20 | 0.54 |
| ▸ | RET | P07949 | 2/20 | 0.54 |
| ▸ | DMPK | Q09013 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10062175 | 1.00 | JAK3 (0.58) | JAK3JAK2JAK1TYK2PKN2 | |
| SCHEMBL350642 | 0.96 | JAK3 (0.58) | JAK3JAK2JAK1TYK2PKN2 | |
| SCHEMBL10062168 | 0.96 | JAK3 (0.58) | JAK3JAK2JAK1TYK2PKN2 | |
| SCHEMBL10062162 | 0.96 | JAK3 (0.58) | JAK3JAK2JAK1TYK2PKN2 | |
| SCHEMBL352835 | 0.96 | JAK3 (0.58) | JAK3JAK2JAK1TYK2PKN2 | |
| SCHEMBL10062179 | 0.96 | JAK3 (0.58) | JAK3JAK2JAK1TYK2PKN2 | |
| SCHEMBL353348 | 0.96 | JAK3 (0.58) | JAK3JAK2JAK1TYK2PKN2 | |
| SCHEMBL353099 | 0.95 | JAK3 (0.61) | JAK3JAK2JAK1TYK2PKN2 | |
| SCHEMBL10062157 | 0.95 | JAK3 (0.61) | JAK3JAK2JAK1TYK2PKN2 | |
| SCHEMBL10062153 | 0.94 | JAK3 (0.60) | JAK3JAK2JAK1TYK2PKN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150315185-A1 | PYRROLO[2,3-b]PYRIDIN-4-YL-AMINES AND PYRROLO[2,3-b]PYRIMIDIN-5-YL-AMINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2015-11-05 | — | — | US | claimed |
| US-9090611-B2 | Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as janus kinase inhibitors | INCYTE CORPORATION (US) | 2015-07-28 | — | — | US | claimed |
| US-20140228346-A1 | PYRROLO[2,3-b]PYRIDIN-4-YL-AMINES AND PYRROLO[2,3-b]PYRIMIDIN-5-YL-AMINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2014-08-14 | — | — | US | claimed |
| US-8741895-B2 | Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2014-06-03 | — | — | US | claimed |
| US-7335667-B2 | Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-4-yl-amines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2008-02-26 | — | — | US | claimed |
| EP-1828181-A2 | PYRROLO[2,3-B]PYRIDIN-4-YL-AMINES AND PYRROLO[2M3-B]PYRIMIDIN-4-YL-AMINES AS JANUS KINASE INHIBITORS | Incyte Corporation (US) | 2007-09-05 | — | — | EP | claimed |
| US-20060183906-A1 | Use as anticancer agents, immunosuppressants for transplants or autoimmune diseases, or against immune reactions (e.g. contact dermatitis or diarrhea) caused by other drugs; e.g. 3-(3-[methyl(1H-pyrrolo[2,3-b]pyridin-4-yl)amino]piperidin-1-yl)-3-oxopropanenitrile | INCYTE CORPORATION | 2006-08-17 | — | — | US | claimed |
| WO-2006069080-A2 | PYRROLO[2,3-B]PYRIDIN-4-YL-AMINES AND PYRROLO[2M3-B]PYRIMIDIN-4-YL-AMINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2006-06-29 | — | — | WO | claimed |
| US-20200093825-A1 | JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES | INCYTE CORPORATION | 2020-03-26 | — | — | US | disclosed |
| EP-2671882-B1 | pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2m3-b]pyrimidin-4-yl-amines as janus kinase inhibitors | INCYTE HOLDINGS CORP (US) | 2018-02-21 | — | — | EP | disclosed |
| EP-2671882-B1 | pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2m3-b]pyrimidin-4-yl-amines as janus kinase inhibitors | INCYTE HOLDINGS CORP (US) | 2018-02-21 | — | — | EP | disclosed |
| US-9879010-B2 | Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b] pyrimidin-5-yl-amines as Janus kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2018-01-30 | — | — | US | disclosed |
| US-9879010-B2 | Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b] pyrimidin-5-yl-amines as Janus kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170349579-A1 | PYRROLO[2,3-B]PYRIDIN-4-YL-AMINES AND PYRROLO[2,3-B]PYRIMIDIN-5-YL-AMINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2017-12-07 | — | — | US | disclosed |
| EP-2349260-A1 | JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES | Incyte Corporation (US) | 2011-08-03 | — | — | EP | disclosed |
| US-20110086835-A1 | Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as janus kinase inhibitors | INCYTE CORPORATION, A DELAWARE CORPORATION | 2011-04-14 | — | — | US | disclosed |
| US-20100113416-A1 | JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES | INCYTE CORPORATION | 2010-05-06 | — | — | US | disclosed |
| WO-2010039939-A1 | JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES | INCYTE CORPORATION (US) | 2010-04-08 | — | — | WO | disclosed |
| US-7335667-B2 | Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-4-yl-amines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2008-02-26 | — | — | US | disclosed |
| US-20060183906-A1 | Use as anticancer agents, immunosuppressants for transplants or autoimmune diseases, or against immune reactions (e.g. contact dermatitis or diarrhea) caused by other drugs; e.g. 3-(3-[methyl(1H-pyrrolo[2,3-b]pyridin-4-yl)amino]piperidin-1-yl)-3-oxopropanenitrile | INCYTE CORPORATION | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086835-A1 | Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as janus kinase inhibitors | JAK3, JAK1, JAK2 | JAK3 1/4885JAK2 3/4885JAK1 2/4885 |
| US-20170349579-A1 | PYRROLO[2,3-B]PYRIDIN-4-YL-AMINES AND PYRROLO[2,3-B]PYRIMIDIN-5-YL-AMINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | JAK3 1/4885JAK2 3/4885JAK1 2/4885 |
| US-20060183906-A1 | Use as anticancer agents, immunosuppressants for transplants or autoimmune diseases, or against immune reactions (e.g. contact dermatitis or diarrhea) caused by other drugs; e.g. 3-(3-[methyl(1H-pyrrolo[2,3-b]pyridin-4-yl)amino]piperidin-1-yl)-3-oxopropanenitrile | JAK1, ZAP70, LCK | JAK3 4/4885JAK2 27/4885JAK1 1/4885 |
| US-20100113416-A1 | JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES | JAK1, JAK3, JAK2 | JAK3 2/4885JAK2 3/4885JAK1 1/4885 |
| US-20150315185-A1 | PYRROLO[2,3-b]PYRIDIN-4-YL-AMINES AND PYRROLO[2,3-b]PYRIMIDIN-5-YL-AMINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | JAK3 1/4885JAK2 3/4885JAK1 2/4885 |
| US-20200093825-A1 | JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES | JAK1, JAK3, JAK2 | JAK3 2/4885JAK2 3/4885JAK1 1/4885 |
| US-20140228346-A1 | PYRROLO[2,3-b]PYRIDIN-4-YL-AMINES AND PYRROLO[2,3-b]PYRIMIDIN-5-YL-AMINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | JAK3 1/4885JAK2 3/4885JAK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.